Molecular pathology of early pancreatic cancer

Cancer Biomarkers

Volumn 9, Issue 1-6, 2011, Pages 421-440

  Remmers, Neeley ^a   Bailey, Jennifer M ^a   Mohr, Ashley M ^a   Hollingsworth, Michael A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

CA19 9; CEACAM; intraductal papillary mucinous neoplasms (IPMN); K ras; MIC1; microRNA; mucin; mucinous cystic neoplasms (MCN); p16 CDKN2A; p53; Pancreatic cancer; pancreatic intraepithelial neoplasia (PanIN); SMAD4 DPC4

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GEMCITABINE; HAPTOGLOBIN A; K RAS PROTEIN; MACROPHAGE INHIBITORY CYTOKINE 1 PROTEIN; MESOTHELIN; MICRORNA; MUCIN 1; MUCIN 2; MUCIN 4; MUCIN 5AC; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P21; PROTEIN P53; PROTEIN S 100; SERUM AMYLOID A; SMAD4 PROTEIN; SONIC HEDGEHOG PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DNA DAMAGE; EPIGENETICS; FAMILIAL CANCER; GENE MUTATION; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MUCINOUS CYSTIC NEOPLASM; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PANCREAS CANCER; PANCREATIC INTRAEPITHELIAL NEOPLASIA; PANCREATITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TELOMERE;

ADENOCARCINOMA; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; MICRORNAS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 82955208232     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0168     Document Type: Article

References (67)

1. American Cancer Society, Cancer Facts & Figures 2008, American Cancer Society Atlanta, 2008, 4.
2. P. Argani, C. Iacobuzio-Donahue, B. Ryu, C. Rosty, M. Goggins, R. E. Wilentz, S. R. Murugesan, S. D. Leach, E. Jaffee, C. J. Yeo, J. L. Cameron, S. E. Kern and R. H. Hruban, Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE), Clin Cancer Res 7 (2001), 3862-3868.
3. J. M. Bailey, J. M. Swanson, T. Hamada, J. P. Eggers, P. K. Singh, T. Caffery, M. M. Ouellette and M. A. Hollingsworth, Sonic hedgehog promotes desmoplasia in pancreatic cancer, Clin Cancer Res 14 (2008), 5995-6004.
4. J. Bara, Cytoplasmic MUC1 in PanIN-1, Clin Cancer Res 14 (2008), 5306.
5. D. P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell 116 (2004), 281-297.
6. U. Bhanot, R. Heydrich, P. Moller and C. Hasel, Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma, Am J Surg Pathol 30 (2006), 754-759.
7. M. Bloomston,W. L. Frankel, F. Petrocca, S. Volinia, H. Alder, J. P. Hagan et al. , MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis, Jama 297 (2007), 1901-1908.
8. T. A. Brentnall, M. P. Bronner, D. R. Byrd, R. C. Haggitt and M. B. Kimmey, Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer, Ann Intern Med 131 (1999), 247-255.
9. K. Brune, S. M. Hong, A. Li, S. Yachida, T. Abe, M. Griffith, D. Yang, N. Omura, J. Eshleman, M. Canto, R. Schulick, A. P. Klein, R. H. Hruban, R. H. Iacobuzio-Donahue and M. Goggins, Genetic and epigenetic alterations of familial pancreatic cancers, Cancer Epidemiol Biomarkers Prev 17 (2008), 3536-3542.
10. D. Cao, A. Maitra, J. A. Saavedra, D. S. Klimstra, N. V. Adsay and R. H. Hruban, Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways, Mod Pathol 18 (2005), 752-761.
11. P. Chaturvedi, A. P. Singh and S. K. Batra, Structure, evolution and biology of the MUC4 mucin, FASEB J 22 (2008), 966-981.
12. X. Chen, Y. Ba, L. Ma, X. Cai, Y. Yin and K. Wang et al. , Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases, Cell Res 18 (2008), 997-1006.
13. D. CChhieng. , E. Benson, I. Eltoum,M. A. Eloubeidi, N. Jhala, D. Jhala, G. P. Siegal, W. E. Grizzle and W. E. Manne, MUC1 andMUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration, Cancer 99 (2003), 365-371.
14. M. A. Eberle, R. Pfützer, K. L. Pogue-Geile, M. P. Bronner, D. Crispin, M. B. Kimmey, R. H. Duerr, L. Kruglyak, D. C. Whitcomb and T. A. Brentnall, A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34, Am J Hum Genet 70 (2002), 1044-1048.
15. A. Esquela-Kerscher and F. J. Slack, Oncomirs - microRNAs with a role in cancer, Nat Rev Cancer 6 (2006), 259-269.
16. M. A. Firpo, D. Z. Gay, S. R. Granger, C. L. Scaife, J. A. DiSario, K. M. Boucher and S. J. Mulvihill, Improved diagnosis of pancreatic adenocarcinoma using Haptoglobin and Serum Amyloid A in a panel screen, World J Surg (2008).
17. M. Gironella, M. Seux, M. J. Xie, C. Cano, R. Tomasini, J. Gommeaux et al. , Tumor protein 53-induced nuclear protein 1 expression is repressed bymiR-155, and its restoration inhibits pancreatic tumor development, Proc Natl Acad Sci U S A 104 (2007), 16170-16175.
18. M. Goggins, Identifying molecular markers for the early detection of pancreatic neoplasia, Semin Oncol 34 (2007), 303-310.
19. D. V. Gold, Z. Karanjawala, D. E. Modrak, D. M. Goldenberg and R. H. Hruban, PAM4-reactive MUC1is a biomarker for early pancreatic adenocarcinoma, Clin Cancer Res 13 (2007), 7380-7387.
20. D. V. Gold, D. E. Modrak, Z. Ying, T. M. Cardillo, R. M. Sharkey and D. M. Goldenberg, New MUC1serum immunoassay differentiates pancreatic cancer from pancreatitis, J Clin Oncol 24 (2006), 252-258.
21. T. Grote and C. D. Logsdon, Progress on molecular markers of pancreatic cancer, Curr Opin Gastroenterol 23 (2007), 508-514.
22. N. Habbe, J. B. Koorstra, J. T. Mendell, G. J. Offerhaus, J. K. Ryu, G. Feldmann et al. , MicroRNA miR-155 is a biomarker of early pancreatic neoplasia, Cancer Biol Ther 8 (2009).
23. U. Halm, T. Schumann, T. Schietke, H. Witzigmann, H. Mossner and V. Keim, Decrease of CA19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer, Br J Cancer 82 (2000), 1013-1016.
24. Y. Hamanaka, Y. Suehiro, M. Fukui, M. Shikichi, K. Imai and Y. Hinoda, Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer, Int J Canc 103 (2003), 97-100.
25. Y. Hashimoto, Y. Murakami, K. Uemura, K. Hayashidani, T. Sudo, H. Ohge, E. Fukuda, FU. Shimamoto, T. Sueda and T. Hiyama, Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas, JGastrointest Surg 12 (2008), 17-29.
26. R. Hassan, Z. G. Laszik, M. Lerner, M. Raffeld, R. Postier and D. Brackett, Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis, Am J Clin Pathol 124 (2005), 838-845.
27. B. S. Hulka, Overview of biological markers, in: Biological markers in epidemiology, B. S. Hulka, J. D. Griffith and T. C. Wilcosky, eds, Oxford University Press New York, 1990, pp. 3-15.
28. M. P. Hunter, N. Ismail, X. Zhang, B. D. Aguda, E. J. Lee, L. Yu et al. , Detection of microRNA expression in human peripheral blood microvesicles, PLoS ONE 3 (2008), e3694.
29. R. H. Hruban, R. H. Goggins, R. H. Parsons and S. E. Kern, Progression Model for Pancreatic Cancer, Clin Can Res 6 (2000), 2969-2972.
30. R. H. Hruban, A. Maitra and A. Goggins, Update on Pancreatic Intraepithelial Neoplasia, Int J Clin Exp Pathol 1 (2008), 306-316.
31. N. Jhala, D. Jhala, S. M. Vickers, I. Eltoum, S. K. Batra, U. manne, M. Eloubeidi, M. Jones and W. E. Grizzle, biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates, Am J Clin Pathol 126 (2006), 572-579.
32. Z Ji. , F. C. Mei, J. Xie andX. Cheng, OncogenicKRAS activates hedgehog signaling pathway in pancreatic cancer cells, J Biol Chem 282 (2007), 14048-14055.
33. A. Jimeno and A. Hidalgo, Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer, Mol Cancer Ther 5 (2006), 787-796.
34. K. Kojima, S. M. Vickers, N. V. Adsay, N. C. Jhala, H. G. Kim, T. R. Schoeb, W. E. Grizzle and C. A. Klug, Inactivation of Smad3 accelerates KrasG12D-mediated pancreatic neoplasia, Cancer Res 67 (2007), 8121-8130.
35. A. H. Ko, J. Hwang, A. P. Venook, J. L. Abbruzzese, E. K. Bergsland and M. A. Tempero, Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer, Br J Cancer 93 (2005), 195-199.
36. J. B. M. Koorstra, S. R. Hustinx, G. J. A. Offerhaus and A. Maitra, Pancreatic Carcinogenesis, Pancreatology 8 (2008), 110-125.
37. C. Li, D. G. Heidt, P. Dalerba, C. F. Burant, L. Zhang, V. Adsay, V. Wicha, M. F. Clarke and D. M. Simeone, Identification of pancreatic cancer stem cells, Cancer Res 67 (2007), 1030-1037.
38. C. D. Logsdon, C. D. Simeone, C. Binkley, T. Arumugam, J. K. Greenson, T. J. Giordano, D. E. Misek, R. Kuick and R. Hanash, Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer, Cancer Res 63 (2003), 2649-2657.
39. A. S. Mall, Analysis of mucins: role in laboratory diagnosis, J Clin Pathol 61 (2008), 1018-1024.
40. R. Mayeux, Biomarkers: Potential uses and limitations, J of American Society for Experimental NeuroTherapeutics 1 (2004), 182-188.
41. P. S. Mitchell, R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-Agadjanyan et al. , Circulating microRNAs as stable blood-based markers for cancer detection, Proc Natl Acad Sci U S A 105 (2008), 10513-10518.
42. E. L. Nichols, P. D. Russ and P. D. Chen, Pancreatic imaging current and emerging technologies, Pancreas 33 (2006), 211-220.
43. C. Niederau and J. H. Grendell, Diagnosis of pancreatic cancer. Imaging studies and tumormarkers, Pancreas 7 (1992), 66-86.
44. K. Ohuchida, K. Mizumoto, K. Fujita, K. Yamaguchi, K. Konomi, E. Nagai, K. Yamaguchi, M. Tsuneyoshi and M. Tanaka, Sonic hedgehog is an early developmental marker of intraductal papillary mucinous neoplasms: clinical implications of mRNA levels in pancreatic juice, J Pathol 210 (2006), 42-48.
45. K. Ohuchida, K. Mizumoto, D. Yamada, H. Fujita, H. Ishikawa, H. Kinomi, E. Nagai, E. Yamaguchi, E. Tsuneyoshi and E. Tanaka, Quantitative analysis of MUC1 and MUC5AC mRNA in pancreatic juice for opreoperative diagnosis of pancreatic cancer, Int J Cancer 118 (2006), 405-411.
46. N. G. Ord́onez, Application of mesothelin immunostaining in tumor diagnosis, Am J Surg Pathol 27 (2003), 1418-1428.
47. N. G. Pasca di Magliano, S. Sekine, S. Ermilov, J. Ferris, A. A. Dlugosz and M. Hebrok, Hedgehog/Ras interactions regulate early stages of pancreatic cancer, Genes Dev 20 (2006), 3161-3173.
48. F. P. Perera and I. B. Weinstein, Molecular epidemiology: recent advances and future directions, Carcinogenesis 21 (2000), 517-524.
49. K. E. Resnick, H. Alder, J. P. Hagan, D. L. Richardson, C. M. Croce and D. E. Cohn, The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform, Gynecol Oncol 112 (2009), 55-59.
50. C. Roldo, E. Missiaglia, J. P. Hagan, M. Falconi, P. Capelli, P. Bersani et al. , MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior, J Clin Oncol 24 (2006), 4677-4684.
51. E. D. Saad, M. C. Machado, M. C. Wajsbrot, M. C. Abramoff, P. M. Hoff, J. Tabacof, A. Katz, S. D. Simon and R. C. Gansl, Pretreatment CA19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine, Int J Gastrointest Cancer 85 (2002), 350-355.
52. W. Schima, W. Ba-Ssalamah, W. Goetzinger, M. Scharitzer and C. Koelblinger, State-of-the-art magnetic resonance imaging of pancreatic cancer, Top Magn Rson Imaging 18 (2007), 421-429.
53. D. T. Silverman, M. Schiffman, J. Everhart, J. Goldstein, K. D. Lillemoe, G. M. Swanson, A. G. Schwartz, L. M. Brown, R. S. Greenberg, J. B. Schoenberg, L. M. Pottern, R. N. Hoover and J. K. J. Fraumeni, Diabetes mellitus, other medical conditions, and familial history of cancer as risk factors for pancreatic cancer, Br J Cancer 80 (1999), 1830-1837.
54. D. M. Simeone, B. Ji, M. Banerjee, T. Arumugam, T. Li, M. A. Anderson, A. M. Bamberger, J. Greenson, R. E. Brand, V. Ramachandran and C. D. Logsdon, CEACAM1, a novel serum biomarker for pancreatic cancer, Pancreas 34 (2007), 436-443.
55. A. P. Singh, P. Chaturvedi and S. K. Batra, Emergine roles of MUC4 in cancer: a novel target for diagnosis and therapy, Cancer Res 67 (2007), 433-436.
56. A. P. Singh, N. Moniaux, S. C. Chauhan, J. L. Meza and S. K. Batra, Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis, Cancer Res 64 (2004), 622-630.
57. M. Singh and A. Maitra, Precursor lesions of pancreatic cancer: molecular pathology and clinical implications, Pancreatology 7 (2007), 9-19.
58. M. H. Swartz, B. K. Surinder, G. C. Varshney, M. A. Hollingsworth, C. J. Yeo, J. L. Cameron, R. E. Wilentz, R. H. Hruban and P. Argani, MUC4 expression increases progressively in pancreatic intraepithelial neoplasia, Am J Clin Pathol 117, 791-796.
59. A. E. Szafranska, M. Doleshal, H. S. Edmunds, S. Gordon, J. Luttges, J. B. Munding et al. , Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign andmalignant tissues, Clin Chem 54 (2008), 1716-1724.
60. M. A. Tarp and H. Clausen, Mucin-type O-glycosylation and its potential use in drug and vaccine development, Biochimica et Biophysica Acta 1780 (2008), 546-563.
61. E. Tassi and A. Wellstein, The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma, Semin Oncol 33 (2006), S50-S56.
62. A. C. Tersmette, G. M. Petersen, G. J. A. Offerhaus, F. C. Falatko, K. A. Brune, M. Goggins, E. Rozenblum, R. E. Wilentz, C. J. Yeo, J. L. Cameron, S. E. Kern and R. H. Hruban, Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer, Clin Cancer Res 7 (2001), 738-744.
63. S. P. Thayer,M. P. diMagliano, P. W. Heiser, C. M. Nielsen, D. J. Roberts, G. Y. Lauwers, Y. P. Qi, S. Gysin, C. Fernández-del Castillo, V. Yajnik, B. Antoniu, M. McMahon, A. L. Warshaw and M. Hebrok, Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis, Nature 425 (2003), 851-856.
64. W. Wang, S. Chen, K. A. Brune, R. H. Hruban, G. Parmigiani and A. P. Klein, PancPRO: risk assessment for individuals with a family history of pancreatic cancer, J Clin Oncol 25 (2007), 1417-1422.
65. M. S. van der Heijden, J. K. Brody, D. A. Dezentje, E. Gallmeier, S. C. Cunningham, M. J. Swartz, A. M. DeMarzo, G. J. Offerhaus, W. H. Isacoff, R. H. Hruban and S. E. Kern, In vivo therapeutic responses contingent on Fanconi anemia/ BRCA2 status of the tumor, Clin Cancer Res 11 (2005), 7508-7515.
66. R. L. Yauch, S. E. Gould, S. J. Scales, T. Tang, H. Tian, C. P. Ahn, D. Marshall, L. Fu, T. Januario, T. Kallop, M. Nannini- Pepe, M. Kotkow, J. C. Marsters, L. L. Rubin and F. J. de Sauvage, A paracrine requirement for hedgehog signalling in cancer, Nature 455 (2008), 406-410.
67. M. Zappata, C. Cohen and M. T. Siddiqui, Immunohistochemical expression of SMAD3, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: utility and potential role, CytoJournal 4 (2007).